Ethnicity can confound results in pharmacogenomic studies. Allele frequencies of loci that influence drug metabolism can vary substantially between different ethnicities and underlying ancestral genetic differences can lead to spurious findings in pharmacogenomic association studies. We evaluated the application of principal component analysis (PCA) in a pharmacogenomic study in Canada to detect and correct for genetic ancestry differences using genotype data from 2094 loci in 220 key drug biotransformation genes. Using 89 Coriell worldwide reference samples, we observed a strong correlation between principal component values and geographic origin. We further applied PCA to accurately infer the genetic ancestry in our ethnically diverse Canadian cohort of 524 patients from the GATC study of severe adverse drug reactions. We show that PCA can be successfully applied in pharmacogenomic studies using a limited set of markers to detect underlying differences in genetic ancestry thereby maximizing power and minimizing false-positive findings.
Introduction
Individuals manifest considerable variability in their response to drug treatment influenced by differences in gender, age, environment as well as genetic determinants. The importance of ethnicity with regards to drug response, including efficacy and risk of toxicity, has been long recognized. 1 Geographic and ethnic differences in the frequency of allele variants in genes that influence drug response such as drug-metabolizing enzymes, transporters and drug targets have been studied since the 1950s and provide a mechanistic basis for at least part of the differences in drug response between populations. [2] [3] [4] In addition, there can be ancestry-specific variants associated with serious adverse drug reactions (ADRs) that occur in a specific ethnicity. An important example is the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome, which has only been found in the Asian populations. 5 between individuals of different genetic ancestry, called population stratification, can cause systematic differences in allele frequencies between cases and controls and lead to false-positive associations. 11 This confounding bias can occur when differences in phenotypic frequencies (e.g. disease or drug toxicity) exist between different genetic subpopulations included in a study. Genetic markers that happen to have a high allele frequency in a subpopulation with a high phenotype frequency, which would also be overrepresented in cases of a study, could lead to spurious associations. 11, 12 Combining different ethnic (sub) populations in one study can also mask true effects leading to false negatives, especially if the populations are ethnically distant. 13 It is therefore necessary to detect and correct for these ancestral genetic differences.
In our national study of severe ADRs in children (genotype-specific approaches to therapy in children or GATC), we are collecting samples from many surveillance sites across Canada.
14 Canada is an ethnically diverse country with visible minorities representing 16% of the total population and almost half the population in large metropolitan areas such as Toronto and Vancouver. 15 Many marriages and common-law unions in Canada are interethnic unions. In Vancouver, for example, up to 8.5% of all unions are between people of different ethnicities. 15 To maximize the statistical power in our pharmacogenomic association study, we need to include as many samples as possible, while minimizing possible false-positive associations due to population stratification. It is vital to control for the genetic ancestry of each sample. However, commonly used ethnic labels are often insufficient and inaccurate proxies of genetic ancestry especially in populations with extensive admixture 16 and some individuals do not know or wrongly assume their ethnicity. It is therefore imperative to apply other methods to determine genetic ancestry.
Several methods have been developed to detect and correct for population stratification in genetic association studies and to estimate genetic ancestry. 17 In many pharmacogenomics studies to date, ancestry informative markers (AIMs) or neutral markers have been used to detect genetic ancestry differences and to assign individuals to different populations using a model-based clustering method. 18, 19 However, this method can be computationally intensive when run on thousands of markers for many individuals at once and the assignment of individuals to ancestry clusters is limited by an a priori assumption of the number of clusters. 20 Genomic control is an alternative adjustment method that relies on a quantitative estimate of the degree of population stratification at reference single nucleotide polymorphisms (SNPs) used to adjust for any stratification that might be present in the tested SNPs. The method relies on the use of unselected random SNPs, because AIMs could artificially inflate the population structure estimate. However, this method is conservative as the same correction factor is used for all investigated markers. 12 Principal component analysis (PCA) is an alternative method to detect and correct for population stratification.
Principal component analysis was first applied to genetic data more than 30 years ago, 21 but it was not until more recently that a solid statistical basis was provided. 20, 22 Principal component analysis is a mathematical method that reduces complex multidimensional data (in this case genotype data) to a smaller number of dimensions by calculating the main axes or 'principal components' (PCs) of variation. These components are orthogonal vectors that capture the maximum variability present in the data. The first component explains the most variation in the data, and each subsequent component accounts for another, smaller part of the variability. When applied to genotype data, these axes of variation have been shown to have a striking relationship with geographic origin. For example, PCA of genotype data from hundreds of thousands of loci in 1387 individuals from across Europe, shows how a twodimensional genetic map based on the first and second PCs closely mirrors the geographic map of Europe and can be used to accurately estimate ancestral origin of samples. 23 The PCA method is simple to use and is an efficient method even with large datasets. Compared with other clustering methods, PCA does not assume a predefined number of expected ancestry clusters, 20 and it has the advantage of being valid when used directly with the SNPs genotyped in a study, provided that those are present at a sufficiently high number. 24 To explore the benefits of PCA in pharmacogenomic studies in Canada, we applied PCA to genotype data from 2094 loci in 220 key drug biotransformation genes to detect and correct for genetic ancestry differences. Using Coriell reference samples we observed a strong correlation between PC values and geographic origin. In addition, we were able to infer the genetic ancestry of samples from the GATC study with high accuracy and to estimate the genetic ancestry of samples of unknown origin. This shows that PCA can successfully be applied in pharmacogenomics to correct for population stratification using a limited set of markers.
Results
We genotyped 89 Coriell worldwide reference samples using a customized pharmacogenomics SNP panel, which was designed to capture the genetic variation of 220 key drug biotransformation genes (see Material and methods section and Supplemental Table 1 ). These samples were chosen to reflect as much genetic variation as possible across the world. We then genotyped 524 patient samples from our GATC study (see Supplemental Table 2 for detailed patient clinical characteristics). To identify underlying genetic ancestry differences we performed PCA on the genotype data from both Coriell reference samples and GATC samples. The first two principal components (PC1 and PC2) represent the main axes of variation within this data and explained 4.62 and 3.46% of variation, respectively. We created scatter plots of these components to visualize these data.
Initially, we plotted PC1 and PC2 of the Coriell reference samples to assess the worldwide pattern of genetic variation for this pharmacogenomics panel ( Figure 1 ). As expected, the cluster pattern resembled a geographic map of the world with the three continents Europe, Asia and Africa each on different points of the 'triangle', consistent with other reports. 25, 26 The first PC distinguished between Europeans and East-Asians, with samples from the Indian subcontinent at intermediate values.
The second component (PC2) distinguished between Africans and non-Africans, with North Africans clustered between sub-Saharan Africans and Europeans. Within the African cluster there was more variability, which reflects the greater genetic diversity in samples of African ethnicity. 27 Next, we plotted PCs of GATC samples for which the selfreported geographic origins of all four grandparents were from the same continental cluster (Europe, Asia or Africa) or India ( Figure 2 ). Of these samples, almost all of the individuals fell within or close to their expected cluster with one notable exception; one of the East-Asian samples fell very close to the Indian cluster. This individual was of Singaporean origin and was therefore labeled as East-Asian. However, according to the census data, 8.9% of residents in Singapore are ethnic Indians. 28 In large studies, participants may not know their ancestry or simply list themselves as 'Canadian'. For example, the Canadian census data list more than 30% of the total population responded as having 'Canadian' origins. 15 Of all GATC samples, parents of 107 individuals identified their family origin as from Canada. When we plotted the PCs of these samples, most individuals fell within the European cluster ( Figure 3 ), which is not surprising given the large number of descendants from immigrants from Europe in Canada. 15 Next, PCA was used to estimate the genetic ancestry of individuals from other geographic or ethnic origins that could not be easily placed in one of the earlier clusters (Figure 4a-e) . For each of these groups only a small number of samples were available in our cohort. Of the six individuals of Caribbean origin, four showed a genetic 31,32 However, demographic information shows that 37.1% of Fijians are of Indian descent, 33 because of immigration in colonial times, so these three samples are likely of Indian descent.
Plotting PC1 and PC2 for individuals of mixed origin showed that the majority of these individuals had intermediate values between their two continental clusters of origin (Figure 5a ). In some cases, there was a clear genetic dose effect. For example, the three individuals with two grandparents from Europe and two from the Caribbean clustered directly between the African and European clusters, whereas one individual with one grandparent from the Caribbean and three from Europe fell closer to the European continental cluster. 
Discussion
Ethnicity has an important function in pharmacogenomics because allele frequencies of genetic variants with significant effects on the biotransformation of drugs can vary considerably between different ethnicities. Mixing populations of different ancestries in an association study can lead to spurious associations. Therefore, it is critically important to determine genetic ancestry of samples to correct for these differences in a pharmacogenomic association study. We describe here the implementation of PCA to easily and reliably ascertain the genetic ancestry of study samples using a limited set of pharmacogenomic markers to assess population stratification within a Canadian study cohort and to correct for these ancestry differences, thereby maximizing the number of samples and power, while minimizing false-positive associations.
When studies are conducted in ethnically diverse cohorts with mixed and sometimes unknown ancestry, such as the GATC pharmacogenomics study of ADRs in children, determining underlying genetic ancestry can be difficult because self-reported ethnic or racial labels are often insufficient proxies for genetic ancestry, or may be undisclosed or unknown by the study participant. Methods that determine genetic ancestry using patient genotype data reflect differences in allele frequencies significantly more accurately. 4, 16, 34 Preferably, these methods should be fast and easy to use even on large datasets without the need for Figure 3 Scatter plot of PC1 and PC2 of GATC samples with self-reported geographic origin from Canada. PCA shows that the genetic structure of most of these individuals is similar to Europeans. 
Use of principal component analysis in pharmacogenomics
H Visscher et al genotyping additional AIMs. Unlike some other methods, PCA of genotype data is fast and easy, can be used on large datasets and does not require any additional genotyping. 20 Other groups have shown that PCA can accurately detect underlying differences in genetic ancestry and estimate an individuals' ancestral origin with high accuracy. 20, 23 We show here that PCA using a limited set of important pharmacogenomic markers in an ethnically diverse cohort can reliably detect underlying differences in genetic ancestry.
We have applied PCA to detect differences in genetic ancestry using 2094 SNPs in 220 key drug biotransformation genes in a varied cohort of samples from the GATC study in patients with geographic origins from around the world. Initially, worldwide Coriell reference samples of predetermined ancestry were used to assess worldwide genetic variation using PCA, and then the PCs of GATC samples were plotted. We found that the first two PCs were highly informative of genetic ancestry and strongly correlated with the known geographic origin of samples. We were also able to determine the genetic ancestry of samples with mixed or unknown origins. Principal component analysis could also detect outliers, such as an individual from Singapore that otherwise may have been misclassified. Furthermore, PCA is a powerful approach to classify groups of patients that do not belong to one of the three continental groups. The PC values could be used to stratify samples into different, genetically similar groups for analysis. However, PCs are continuous axis of variation, 20 and therefore, in most cases, it will be more appropriate to use them as continuous covariates in regression analyses. This strategy will increase the power of a study because all participants can be analyzed together, while at the same time correct for population stratification.
Our ability to discriminate between samples from different ethnic or geographic origins and to detect further population stratification will likely increase when more SNPs are investigated in our pharmacogenomics panel. 22 Using PCA on hundreds of thousands of markers, several groups were able to show detailed underlying genetic differences with high correlation between the genetic and geographic map in Europe. 23, 35 Increasing the number of samples might further increase the ability to detect additional population structure. Currently, samples with genetic ancestry from Europe were relatively overrepresented in our cohort compared with the number of samples from Asian and especially African ancestry. Genetic diversity in certain regions such as Africa or India is extensive 27, 36 and including more samples from these origins and from other geographic locations will likely further improve this method.
Increasing the number of SNPs or including more samples, however, will not likely change the overall worldwide map when plotting PC1 and PC2, but investigating plots of subsequent PCs might show additional geographic structure in subpopulations. 25, 26 In this study, visual inspection of plots of subsequent components (PC3-PC10) did not show further discrimination possible between subpopulations (data not shown).
To test the robustness of PCA and to estimate the minimum number of SNPs needed in our SNP panel to detect population structure, we performed PCA using sets of different numbers of randomly selected SNPs. Plotting the first two components, using 1000 or 500 randomly selected SNPs, shows a similar cluster pattern as using the full dataset (Supplemental Figure 1a and b) . Using less SNPs (250, 100 or even as low as 50) still shows some evidence of the continental clusters (Supplemental Figure 1c-e) , however, the clusters are close together and there is substantial variability within clusters. The plots suggest that at least 250-500 SNPs are needed to discriminate clearly between clusters.
The pharmacogenomic SNP genotyping panel consisted of different classes of SNPs (i.e. non-synonymous, synonymous, intronic, etc.). To evaluate whether the results only depended on a particular class, we applied PCA to the dataset using only intronic (n ¼ 972) or only non-synonymous (n ¼ 332) SNPs. Again, plotting the first two components using either group of SNPs shows a similar cluster pattern as using the full dataset (Supplemental Figure 2) . This suggests that the observed structure does not depend on a particular class of SNP, as long as the dataset is sufficiently large. Removing the AIMs, which were included in the design of the SNP panel, from the full dataset also did not change the results (data not shown).
Principal component analysis to detect population structure works well if the genetic markers are independent. However, in extreme cases of linkage disequilibrium (LD) the results can be difficult to interpret. Components can be correlated with genotype patterns in large blocks in which all markers are in LD and distort the eigenvalue structure if not corrected for. 22 In this study, many genes have been densely genotyped with varying patterns of LD. To assess whether LD between markers might influence our results, we removed a marker from every pair of markers that were in tight LD, so that only unlinked markers were included in the genotype dataset (n ¼ 778). We then applied PCA to this reduced dataset and plotted the first two components (PC1 and PC2) of the Coriell reference samples (Supplemental Figure 3) . The cluster pattern showed in this analysis is very similar to the initial PCA using the full set of markers, which suggests that LD between markers in our dataset did not influence our results, which is consistent with what has been shown earlier. 25 Several other factors such as inter-assay variability or cryptic relatedness can potentially lead to evidence for structure in genotyping data and be mistaken for population stratification. 20, 37, 38 However, inter-assay variability for our genotyping panel was low with a concordance in genotyping results for replicates of greater than 99.9% (n ¼ 132). We also assessed cryptic relatedness, or hidden distant kinship, by calculating the average identity by state, but found no cryptic related individuals. These factors will therefore not have influenced the results substantially.
We have shown that PCA applied to a limited set of pharmacogenomic data can be used to detect important underlying differences in genetic ancestry. Principal 
Material and methods
Populations and samples Initially, DNA samples from different reference populations were selected and obtained from the Human Variation Panel from the Coriell Cell Repositories (Coriell Institute for Medical Research, Camden, NJ, USA): 10 Northern-European, 9 Italian, 9 Hungarian, 9 Indo-Pakistani, 9 Chinese, 9 Japanese, 9 Southeast Asians, 9 African-American, 7 Africans North of the Sahara and 9 Africans South of the Sahara.
A total of 524 patient DNA samples were then analyzed as part of the GATC project, a national project established in Canada to identify novel predictive genomic markers of severe ADRs in children 14 . Patients who suffered any serious ADR were enrolled as well as drug-matched controls. Patients were treated for a variety of diseases with many different drugs. There were slightly more males than females (57% vs 43%). No siblings or relatives were included in this analysis. As part of this study, parents were asked for the geographic origin of the four grandparents of their child. See Supplemental Table 2 for more details on patient characteristics. Written informed consent was obtained from each study participant or parent and the study was approved by the ethics committees of all the participating universities and hospitals. DNA was extracted from blood, saliva or buccal swabs using the QIAamp 96 DNA Blood kit (Qiagen, ON, Canada).
Genotyping
All DNA samples were genotyped for 2977 SNPs using a customized Illumina GoldenGate SNP genotyping assay (Illumina, San Diego, CA, USA), which was designed to capture the genetic variation of 220 key drug biotransformation genes (i.e. phases I and II drug-metabolism enzymes, drug transporters, drug targets, drug receptors, transcription factors, ion channels and other disease-specific genes related to the physiological pathway of ADRs). The panel consisted of 1536 tagSNPs identified using the LD Select algorithm to select a maximally informative set of tag SNPs to assay in the candidate genes. 39 The tag SNP selection was performed using data from the International HapMap project that included all four populations (CEU, CHB, JPT, YRI) with a threshold for the LD statistic r 2 of 0.8, and a minor allele frequency of more than 0.05. Furthermore, 1536 functional SNPs were included that had been identified primarily by literature review or from public databases that cause nonsynonymous amino-acid changes or have been or could be associated with changes in enzyme activity or function. Ninety-five SNPs were both tag and functional SNP, so a total of 2977 unique SNPs were included. The initial design also included 50 AIMs. All SNPs were manually clustered in the BeadStudio software suite. SNPs that could not be clustered or were non-polymorphic were excluded from further analyses (883 SNPs). In total 2094 SNPs were available for analysis. See Supplemental Table 1 for more details on the SNP panel. Researchers who wish to obtain more information can contact the corresponding author.
Data quality control
Samples with a call rate of less than 95% were not included in the analysis. The average genotyping call rate for all samples was 99.3%.
To evaluate our genotyping platform for inter-assay variability or batch-to-batch variation, we genotyped all Coriell samples as well as a subset of patient samples in replicate. In addition, a positive control sample with known genotypes was included in each genotyping batch. The concordance of genotype calls between these replicate genotyped samples was greater than 99.9% (n ¼ 132).
The average identity by state was computed for each subject pair, as implemented in PLINK, 40 but no duplicates (499% identity) or (cryptic) related individuals (86-98% identity) were found.
Principal component analysis
Principal components of the SNP genotype data from the Coriell reference samples and the GATC patient samples were calculated using the Eigenstrat method 20 implemented in HelixTree 6.4.2 (Golden Helix, Bozeman, MT, USA) using default settings. Applying PCA to the genotype data consisting of 2094 SNPs reduced this multidimensional dataset into a smaller number of PCs, which each explains subsequent parts of variation. The first and second PCs that explain the largest portion of variation, 4.62 and 3.46%, respectively, were plotted using Excel (Microsoft, Redmond, WA, USA).
A second PCA was performed using only markers not in LD (n ¼ 778). Linkage disequilibrium between all pairs of markers was calculated in HelixTree. A marker was removed from every pair of markers that were in LD, so that only unlinked markers (r 2 o0.2) were included.
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